ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline has opened a $70 million facility in Montrose, Scotland, where it will manufacture fluticasone furoate and vilanterol trifenatate, the active pharmaceutical ingredients in its Ellipta respiratory inhaler. Last year, GSK launched a $57 million plant at the site, which produces aluminum salt adjuvants for vaccines. CEO Emma Walmsley says GSK has targeted Montrose for further growth based on new vaccines and medicines for respiratory illness and HIV.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X